Mobile Menu - OpenMobile Menu - Closed

REFRESHER: What You Need to Know About FDA’s User Fees in Four Short Videos

Aug 7, 2017
Reauthorizing User Fees is a Win for Patients Looking for New Cures and Treatments and Manufacturers of Life-Saving Drugs and Devices

WASHINGTON, DC – Ever heard of an UFA? They’re FDA’s critically important user fee programs. H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017 will reauthorize all four user fee programs for five years.

They may be filled with wonky acronyms, but they will help foster innovative new treatments and medical devices, help lower the cost of drugs, and deliver hope to patients everywhere.

The House passed FDARA unanimously by voice vote in July, and the Senate passed it by a vote of 94-1 last week.

Now, it’s headed to President Trump’s desk to be signed into law. Check out these quick videos for a refresher (or to get up to speed on these vital programs) before FDARA becomes law.

All too often, our laws and regulations don’t allow medical advancements to be implemented soon enough. FDARA will help these important innovations reach patients sooner and increase competition in the marketplace. Click HERE to watch the video.

More than two million Americans work in the medical device sector and more than 4 million Americans work in the biopharmaceutical industry. These are important jobs that we need to keep – and grow – here at home. Click HERE to watch the video.

FDARA improves the process of reviewing and approving innovative new drugs, which increases competition and helps lower costs across the marketplace. Click HERE to watch the video.

Anything is possible with today’s medical advancements. Thanks to science, we’ve made the idea of an artificial pancreas a reality, FDARA boosts these important efforts enabling patients to live better and healthier lives. Click HERE to watch the video.